Research Papers:
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1901 views | HTML 2997 views | ?
Abstract
Sung-Hsin Kuo1,5,6,7, Shi-Yi Yang8, San-Lin You9,10, Huang-Chun Lien2, Ching-Hung Lin1,6, Po-Han Lin3, Chiun-Sheng Huang4
1Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
2Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
3Department of Medical Genetics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
4Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
5Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
6Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
7National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan
8Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
9School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan
10Big Data Research Center, Fu-Jen Catholic University, New Taipei, Taiwan
Correspondence to:
Chiun-Sheng Huang, email: [email protected]
Keywords: genetic polymorphism, GWAS, breast cancer, prognostic factor, survival
Received: August 01, 2016 Accepted: January 03, 2017 Published: February 02, 2017
ABSTRACT
In this study, we investigated whether single nucleotide polymorphisms (SNPs) identified by genome-wide association study (GWAS) (MAP3K1, FGFR2, TNRC9, HCN1, and 5p12), and SNPs involved in the metabolism of estrogen (CYP19, COMT, ESR1, and UGT1A1), tamoxifen (CYP2C9, CYP2C19, CYP3A5, and CYP2D6), and chemotherapeutic agents (ABCB1, ALDH3A1, and CYP2B6) are associated with the prognoses of 414 hormone receptor (HR)-positive early breast cancers with negative or 1 to 3 nodal metastases. At a median follow-up period of 10.6 years, 363 patients were alive, and 51 (12.3%) had died. Multiple-adjusted hazard ratios (aHRs) and the corresponding 95% confidence intervals for distant disease-free survival (DDFS), disease-free survival (DFS), and overall survival (OS) in association with the genotypes of 34 SNPs from the above-mentioned 16 genes were evaluated, using the stepwise selection Cox model. We found that the SNP, ESR1-codon325 rs1801132 (G/G+G/C), was associated with a longer DDFS, whereas UGT1A1 rs4148323 (A/A+A/G), and HCN1 rs981782 (A/A+A/C) were significantly associated with poorer DDFS. MAP3K1 rs889312 (C/C) and CYP2B6 rs3211371 (T/C) were significantly associated with poor DFS, DDFS and OS. Among premenopausal women, MAP3K1 rs889312 (C/C), CYP2B6 rs3211371 (T/C), CYP2B6 rs4802101 (T/T), ABCB1 rs2032582 (C/C), and ALDH3A1 rs2231142 (G/G) were significantly associated with poor DDFS, DFS, or OS. Our results provide additional evidence that genetic polymorphisms observed in SNPs are associated with the prognoses of patients with HR-positive breast cancers; this may indicate different treatment strategies for these patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14995